Opko Health (OPK) stock in plain English
Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.
Change shown by the quote provider. Data may be delayed.
What does Opko Health (OPK) do?
Opko Health Inc (OPK) is a U.S.-listed company in Healthcare (Diagnostics & Research). What it does: Provides routine and esoteric laboratory diagnostic testing to healthcare providers across the United States. Combines a nationwide clinical testing laboratory business with proprietary prescription drug development and licensing. It is worth $1.20B on the market and sold $502.29M over the last year.
- Market cap
- $1.20B
- P/E ratio
- None (reported a loss)
- Annual sales
- $502.29M
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Brief updated
- Nov 16, 2026
Brands and businesses behind OPK
- BioReference Health: Operates clinical laboratories providing diagnostic testing services to doctors and hospitals for direct fee revenue.
- Rayaldee: Prescription medicine that generates sales revenue treating secondary hyperparathyroidism in chronic kidney disease patients.
- 4Kscore: Proprietary blood test generating diagnostic fee revenue by assessing risk for aggressive prostate cancer.
- GenPath: Specialized oncology testing unit earning revenue through advanced cancer and hereditary genetics screening.
OPK’s flags, in plain English
Each flag is a number from Opko Health’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 16, 2026.
Stupid Cash
Can pay this year's bills 5 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.
Insiders Hold
Insiders own 48.6% of the company. The people who run the company own a meaningful slice of it, so they gain or lose along with other shareholders.
Low debt
Low debt, only 46% of shareholder equity. The company owes very little compared with what it earns, so a bad year is less likely to force its hand.
Burning Cash
Losing money, profit margin of -29.5%. The business spends more cash than it brings in. It has to cover the gap with cash on hand, new loans or new shares.
2 more risk notes open with the free trial. Try it free for 7 days.
Questions about OPK
How big is Opko Health?
Opko Health’s market cap is $1.20B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $502.29M: what customers paid the company over the last year, before any costs.
What is OPK’s P/E ratio?
OPK has no P/E ratio right now. The company reported a loss, so there is no yearly profit to price.
What could go wrong with OPK?
The clinical laboratory business faces ongoing pressure from declining reimbursement rates by private insurers and Medicare. That is one risk on Opko Health’s card. Its first risk flag is Burning Cash, explained above. The card holds 2 more risk notes for trial accounts. A flag reads what the company reported. It does not predict the price.
Where do these numbers come from?
From Opko Health’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. OPK’s filings on SEC.gov. The Margin Monkey is research, not advice.
